Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 11/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12419012 | 0.82 | CYP4F2 (0.41) | GAASMN1; SMN2 | |
| SCHEMBL12419088 | 0.77 | MMP13 (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12414160 | 0.76 | GAA (0.49) | GAAALDH1A1RECQLFAAHNR1I2 | |
| SCHEMBL12419011 | 0.72 | NPC1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11955653 | 0.70 | GAA (0.43) | GAAALDH1A1RECQLFAAHNR1I2 | |
| SCHEMBL48239 | 0.70 | ALDH1A1 (0.75) | GAAALDH1A1RECQLNR1I2APP | |
| SCHEMBL28106819 | 0.70 | ALDH1A1 (0.75) | GAAALDH1A1RECQLNR1I2APP | |
| SCHEMBL10623263 | 0.70 | GAA (0.58) | GAAALDH1A1RECQLNR1I2SMN1; SMN2 | |
| SCHEMBL10425033 | 0.69 | GAA (0.49) | GAAALDH1A1RECQLNR1I2SMN1; SMN2 | |
| SCHEMBL12410588 | 0.69 | GAA (0.42) | GAAALDH1A1RECQLFAAHNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110171166-A1 | POLYMER CONJUGATES OF OSTEOCALCIN PEPTIDES | NEKTAR THERAPEUTICS | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171166-A1 | POLYMER CONJUGATES OF OSTEOCALCIN PEPTIDES | SOST, PTMS, ALPP | GAA 1124/4885ALDH1A1 2086/4885RECQL 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.